Inflammation
|
0.510 |
Therapeutic
|
phenotype |
CTD_human |
The supplementation of FGF-2 and BDNF attenuated various parameters of inflammation, including astrocytosis, microcytosis and IL-1β expression.
|
21087489 |
2010 |
Inflammation
|
0.510 |
Biomarker
|
phenotype |
RGD |
Strain-dependent increases in retinal inflammatory proteins and photoreceptor FGF-2 expression in streptozotocin-induced diabetic rats.
|
19474406 |
2009 |
Inflammation
|
0.510 |
Biomarker
|
phenotype |
LHGDN |
Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668.
|
12057924 |
2002 |
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
RGD |
Parallel up-regulation of FGF-2 and hyaluronan during development of cardiac hypertrophy in rat.
|
18196276 |
2008 |
Cardiomegaly
|
0.500 |
Biomarker
|
phenotype |
CTD_human |
Fibroblast growth factor-2 mediates pressure-induced hypertrophic response.
|
10491406 |
1999 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Reprogramming COX-2, mPGES-1 and CYP4A mediated-AA metabolism in glioma by flavonoid ISL inhibits the angiogenic Akt- FGF-2/TGF-β/VEGF signaling through ceRNA effect of miR-194-5p and lncRNA NEAT1, and may serve as a novel therapeutic strategy for human glioma.
|
31438982 |
2019 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
|
29887238 |
2018 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, siRNA was used to silence the expression of bFGF in glioma cell lines including U87 and U251 followed by chemotherapy of temozolomide (TMZ).
|
27189511 |
2016 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, this study demonstrated that miR-195 suppressed PCa cell metastasis by downregulating FGF2. miR-195 restoration may be considered as a new therapeutic method to treat metastatic PCa.
|
26650737 |
2015 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated that bFGF promoted EMT and motility of human prostate cancer PC-3 cells.
|
25088797 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on our previous successful construction of a lentivirus-mediated alphastatin (an endogenous angiogenesis inhibitor) gene transfer system and our findings that alphastatin exhibited potent inhibitory effects on the migration and differentiation of human umbilical vein endothelial cell lines (HUVECs) induced by vascular endothelial growth factor (VEGF) or basic fibroblast growth factor (bFGF) in vitro, here, we investigated the effect of using lentiviral vectors to overexpress alphastatin in human glioma cells to show whether sustained long-term expression of alphastatin diminishes tumor growth in a xenograft glioma model.
|
23242200 |
2013 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57.
|
23243019 |
2013 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
An optimal siRNA sequence specific for bFGF mRNA was cloned into an adenoviral vector and transfected into three glioma cell lines: U251, A172, and LN229.
|
20221717 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results offer a potential mechanism for using Ad-bFGF-siRNA as a gene therapy for glioma.
|
21906308 |
2011 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In human prostate cancer DU145 cells, FSK (1 μM) and FGF2 (10 ng/ml) increased BSP and Runx2 mRNA and protein levels at 3 and 12h, respectively.
|
20965237 |
2011 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, a bFGF-targeted siRNA was delivered to the glioma cell line, U251, using adenovirus (Ad-bFGF-siRNA) and the expression of connexin 43 and its phosphorylation state were evaluated.
|
20074329 |
2010 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A glioblastoma stem cell (GSC) line, GSC11, grows as neurospheres in serum-free media supplemented with EGF (epidermal growth factor) and bFGF (basic fibroblast growth factor), and, if implanted in nude mice brains, will recapitulate high-grade glial tumors.
|
20199106 |
2010 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
We present a positive correlation between the autocrine expression of YY1 and TGF-beta 1, IGF-1 and FGF-2, known to be involved in the progression of gliomas and meningiomas.
|
19235591 |
2009 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We present a positive correlation between the autocrine expression of YY1 and TGF-beta 1, IGF-1 and FGF-2, known to be involved in the progression of gliomas and meningiomas.
|
19235591 |
2009 |
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Caveolin-1 (cav-1) and the cancer-promoting growth factors vascular endothelial growth factor (VEGF), transforming growth factor beta1 (TGF-beta1), and fibroblast growth factor 2 (FGF2) are often found to be upregulated in advanced prostate cancer and other malignancies.
|
19903767 |
2009 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In particular, we demonstrate that HMW FGF-2 has unique features in inhibiting glioma cell proliferation.
|
18930044 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The G-rich promoter and G-rich coding sequence of basic fibroblast growth factor are the targets of thalidomide in glioma.
|
18687660 |
2008 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
|
17637743 |
2008 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data indicate that endogenously synthesized fibrinogen promotes the growth of lung and prostate cancer cells through interaction with FGF-2.
|
17949478 |
2008 |
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor 2 (FGF2) is a pleiotropic growth factor that has been implicated in prostate cancer formation and progression.
|
16940294 |
2006 |